Sonoma Pharmaceuticals (SNOA) Change in Account Payables (2010 - 2026)
Sonoma Pharmaceuticals' (SNOA) quarterly Change in Account Payables came in at $282000.0 in Q1 2026, up 162.95% year-on-year from $107246.2 in Q1 2025, and up 23.14% quarter-over-quarter from $229000.0 in Q4 2025.
Sonoma Pharmaceuticals (SNOA) Change in Account Payables (2010 - 2026) Analysis & Trends
Sonoma Pharmaceuticals' Change in Account Payables history runs 17 years deep, the most recent figure standing at $282000.0 for Q1 2026.
- On a quarterly basis, Change in Account Payables rose 162.95% year-over-year to $282000.0 in Q1 2026; TTM through Mar 2026 was $871000.0, a 109.38% increase from a year earlier, with the FY2026 full-year figure at $871000.0, up 109.38% from the prior year.
- Change in Account Payables climbed to $282000.0 in Q1 2026 per SNOA's latest filing, from $229000.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $1.0 million in Q2 2025 and bottomed at -$981000.0 in Q3 2022.
- The 5-year median for Change in Account Payables is $37000.0 (2024), against an average of $10411.8.
- Across the five-year window, Change in Account Payables soared 1410.71% in 2022 and sank 1900.0% in 2025, its largest moves.
- Year by year, Change in Account Payables stood at $205000.0 in 2022, then slumped by 170.24% to -$144000.0 in 2023, then surged by 547.92% to $645000.0 in 2024, then tumbled by 64.5% to $229000.0 in 2025, then grew by 23.14% to $282000.0 in 2026.
- Per Business Quant, the three latest SNOA Change in Account Payables figures stand at $282000.0 (Q1 2026), $229000.0 (Q4 2025), and -$666000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 62.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 30.60 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 32.70 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Sonoma Pharmaceuticals | 179.80 | -2.40 Mn | 2.18 Mn | 282,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 282,000.00 |
| Mar 31, 2026 | 282,000.00 |
| Dec 31, 2025 | 229,000.00 |
| Dec 31, 2025 | 229,000.00 |
| Sep 30, 2025 | -666,000.00 |
| Sep 30, 2025 | -666,000.00 |
| Jun 30, 2025 | 1.03 Mn |
| Jun 30, 2025 | 1.03 Mn |
| Mar 31, 2025 | -448,000.00 |
| Mar 31, 2025 | -448,000.00 |
| Dec 31, 2024 | 645,000.00 |
| Dec 31, 2024 | 645,000.00 |
| Sep 30, 2024 | 37,000.00 |
| Sep 30, 2024 | 37,000.00 |
| Jun 30, 2024 | 182,000.00 |
| Jun 30, 2024 | 182,000.00 |
| Mar 31, 2024 | -266,000.00 |
| Mar 31, 2024 | -266,000.00 |
| Dec 31, 2023 | -144,000.00 |
| Dec 31, 2023 | -144,000.00 |